Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 10;6(1):e000303.
doi: 10.1136/lupus-2018-000303. eCollection 2019.

10 most important contemporary challenges in the management of SLE

Affiliations
Review

10 most important contemporary challenges in the management of SLE

Renaud Felten et al. Lupus Sci Med. .

Abstract

From a 1-year survival of less than 50% before the discovery of glucocorticoids to over 90% at 10 years in most dedicated centres, the spectrum of SLE has profoundly evolved. Despite this improvement, several major challenges currently remain. The aim of this review is to analyse what are, according to us, the 10 most important contemporary challenges in the management of SLE. Among those are the need to treat to target to favour disease remission (or low disease activity), limit the use of glucocorticoids, derive more comprehensive tools for the evaluation of disease activity, develop more effective drugs (yielding successful trials), dissect the heterogeneity of the disease both at the molecular and genetic levels, identify relevant biomarkers for individualised treatment, manage fertility and pregnancy, tackle comorbidities such as cardiovascular risk, the prevention of infections and osteoporosis, improve the network of care (from the patients' perspective), and favour a holistic approach (integrating fatigue, adherence to treatment, physical activity). Altogether, these 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.

Keywords: damage; disease activity; glucocorticoids; review; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LA has received honoraria and/or funding from Amgen, AstraZeneca, GSK, Janssen-Cilag, LFB, Lilly, Menarini France, Novartis, Pfizer, Roche-Chugaï and UCB. RF has received honoraria from AbbVie, BMS and Pfizer. MR has received funding from GSK and Boehringer Ingelheim. TM has received honoraria and/or funding from Amgen, GSK, CSL Behring, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche-Chugaï and Sanofi-Genzyme.

References

    1. Arnaud L, Fagot J-P, Mathian A, et al. . Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev 2014;13:1082–9. 10.1016/j.autrev.2014.08.034 - DOI - PubMed
    1. van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international Task Force. Ann Rheum Dis 2014;73:958–67. 10.1136/annrheumdis-2013-205139 - DOI - PubMed
    1. van Vollenhoven R, Voskuyl A, Bertsias G, et al. . A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61. 10.1136/annrheumdis-2016-209519 - DOI - PubMed
    1. Little J, Parker B, Lunt M, et al. . Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort. Rheumatology 2018;57:677–87. 10.1093/rheumatology/kex444 - DOI - PMC - PubMed
    1. Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, et al. . Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med 2016;3:e000157 10.1136/lupus-2016-000157 - DOI - PMC - PubMed

LinkOut - more resources